Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference
November 13 2018 - 4:30PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ophthalmology and
rare diseases, today announced the company will be participating in
the upcoming 30th Annual Piper Jaffray Healthcare Conference in New
York, NY.
Adverum’s management is scheduled to present on Tuesday,
November 27, 2018 at 2:30pm Eastern Time. Interested parties may
access a live and archived webcast of the presentation on the
“Investors” section of the company’s website at: www.adverum.com.
The webcast will be available on the company’s website for at least
two weeks following the event.
About Adverum Biotechnologies,
Inc.Adverum is a clinical-stage gene therapy company
targeting unmet medical needs in ophthalmology and rare diseases.
Adverum develops gene therapy product candidates designed to
provide durable efficacy by inducing sustained expression of a
therapeutic protein. Adverum has collaboration agreements with
Regeneron Pharmaceuticals to research, develop, and commercialize
gene therapy products for ophthalmic diseases and Editas Medicine
to explore the delivery of genome editing medicines for the
treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development, novel vector discovery
and in-house manufacturing expertise, specifically in scalable
process development, assay development, and current Good
Manufacturing Practices quality control. For more information,
please visit www.adverum.com.
Investor and Media Inquiries:
Katherine Bock
Vice President Investor Relations & Corporate Communications
Adverum Biotechnologies, Inc.
650-656-9347
kbock@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024